|Bid||14.28 x 900|
|Ask||14.33 x 1300|
|Day's Range||14.20 - 14.80|
|52 Week Range||10.00 - 83.10|
|Beta (5Y Monthly)||1.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.56|
SAN DIEGO, Jan. 08, 2020 -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet.
AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
If you're interested in AnaptysBio, Inc. (NASDAQ:ANAB), then you might want to consider its beta (a measure of share...
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was AnaptysBio, Inc. (NASDAQ:ANAB). AnaptysBio, Inc. (NASDAQ:ANAB) was in 15 hedge […]
The WeTrader Paper Trading Competition , a 5-week paper trading contest hosted by the zero-commission trading platform Webull, has officially ended. Here’s a look at how the 83 contestants—the top 10 portfolios ...
AnaptysBio stock crashed Friday after the biotech said its experimental eczema treatment failed to pass muster in a Phase 2 study. Shares fell to their lowest-ever point in high volume.
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -2.68% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Benzinga Pro's Stocks To Watch For Friday Disney (DIS) - Shares traded 6% higher following better-than-expected Q4 earnings but a slight sales miss. Analysts who responded to the earnings report were mostly ...
Topline Data From Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Failed to Meet Primary EndpointReported Positive Topline Data from Interim.
AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data from its ATLAS trial, a Phase 2b randomized, double-blinded, placebo-controlled, multi-dose study in approximately 300 adult patients treated with etokimab in moderate-to-severe atopic dermatitis. The Company will be receiving additional data and plans to provide a detailed update in the first quarter of 2020.
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the second quarter and hedging or reducing many of […]
Investing in stocks comes with the risk that the share price will fall. And unfortunately for AnaptysBio, Inc...
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE/Nasdaq-listed biotech stocks hit 52-week highs on Oct. 1. Down In The Dumps (Biotech stocks hitting 52-week ...
AnaptysBio stock toppled Tuesday after the biotech company's psoriasis treatment failed to enthuse investors. The company tested just two patients vs. analyst expectations for 10 patients.
AnaptysBio Inc (NASDAQ: ANAB ) released topline results Monday from an interim data analysis from a midstage study of its investigational asset ANAB019, which being evaluated for moderate-to-severe generalized ...
AnaptysBio shares fell to their lowest level in two years after the biotech company released Phase II results that analysts questioned because they included only two participants. SunTrust was "admittedly underwhelmed by the fact that interim data only included 2 subjects while [the] full study is expect[ed] to enroll 10 subjects," according to a Sept. 30 note from analyst Joon Lee, who has a buy recommendation and $93 target on the stock.
Interim analysis conducted with first two patients to complete 16-week (Day 113) ANB019 monotherapy studyBoth patients achieved the primary endpoint of disease score improvement.
SAN DIEGO, Sept. 27, 2019 -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet.